Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Ildong Pharmaceutical Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Yun Paul Woongsup

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	keine Daten

Jüngste Management Updates

Recent updates

If You Had Bought Ildong Pharmaceutical (KRX:249420) Shares A Year Ago You'd Have Earned 18% Returns

Jan 01

Geschäftsführer

Yun Paul Woongsup

no data

Amtszeit

Yun Paul Woongsup is Chief Executive Officer of Ildong Pharmaceutical Co., Ltd.

Ildong Pharmaceutical Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Ildong Pharmaceutical Co., Ltd., Annual General Meeting, Mar 22, 2024

Ildong Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Recent updates

Ildong Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: ₩2,920 loss per share (vs ₩5,375 loss in FY 2022)

New major risk - Revenue and earnings growth

Ildong Pharmaceutical Co., Ltd., Annual General Meeting, Mar 22, 2024

Ildong Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 08, 2024

New major risk - Share price stability

New minor risk - Shareholder dilution

Ildong Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: ₩389 loss per share (vs ₩4,855 loss in 1Q 2022)

Full year 2022 earnings released: ₩5,375 loss per share (vs ₩4,192 loss in FY 2021)

Ildong Pharmaceutical Co., Ltd. Files a New Drug Application with the MFDS for the Indication of SARS-CoV-2 Infection, and This Application Has Been Accepted for Review by MFDS

Third quarter 2022 earnings released: ₩626 loss per share (vs ₩197 loss in 3Q 2021)

Price target increased to ₩50,000

Ildong Pharmaceutical Starts Phase 1 Study of New Diabetes Therapy in Germany

New 90-day low: ₩17,800

Ildong Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Ildong Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Feb 19, 2021

Ildong Pharmaceutical Co., Ltd. announced that it has received KRW 100 billion in funding

If You Had Bought Ildong Pharmaceutical (KRX:249420) Shares A Year Ago You'd Have Earned 18% Returns

New 90-day high: ₩20,450

New 90-day high - ₩18,450

Ildong Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 13, 2020

Geschäftsführer

Amtszeit